CREBBP and nasopharyngeal carcinoma: By using ICG-001, a specific CREB-binding protein (CBP)/β-catenin antagonist in Epstein- Barr Virus (EBV) positive nasopharyngeal carcinoma, Chan et al. observed a reduction in the cancer-stem-cell-like population of cells that, amongst other outcomes, was associated with an increase in miR-145.